

The specific grouping strategies for each subgroup are detailed

First author/year	outcome	HSP	Method	Specimen type	Follow-up start time	Tumor stage	treatments	Sample Size	Gender ratio
Elizabeth M Tweedle (2010)	OS	HSP27	IHC	Primary tissue	Post-diagnosis	Mixed	With chemotherapy	>200	≥1.5
Feng Wang (2012)	OS	HSP27	IHC	Primary tissue	Postoperative	Mixed	With chemotherapy	≤200	<1.5
Karina Bauer cohort 1 (2012)	OS	HSP70	IHC	Primary tissue	Postoperative	Mixed	With chemotherapy	>200	<1.5
Karina Bauer cohort2 (2012)	OS	HSP27	IHC	Primary tissue	Postoperative	Mixed	No chemotherapy	>200	<1.5
Maria Anna Kalioraki (2019)	OS	HSP27	PCR	Primary tissue	Postoperative	Mixed	No chemotherapy	≤200	<1.5
Jan Hrudka cohort 1 (2021)	OS	HSP27	IHC	Primary tissue	Postoperative	Mixed	No chemotherapy	>200	<1.5
Jan Hrudka cohort 2 (2021)	OS	HSP70	IHC	Primary tissue	Postoperative	Mixed	No chemotherapy	>200	<1.5
Jan Hrudka cohort 3 (2021)	OS	HSP110	IHC	Primary tissue	Postoperative	Mixed	No chemotherapy	>200	<1.5
Tadanobu Shimura (2025)	OS	HSP27	IHC	Primary tissue	After the initial discharge	Mixed	No chemotherapy	≤200	<1.5
Shaoshan Yang (2020)	OS	HSP40	IHC	Primary tissue	NA	NA	No chemotherapy	≤200	≥1.5
Koichiro Mori (2017)	OS	HSP47	IHC	Primary tissue	Postoperative	Nonmetastatic	No chemotherapy	≤200	<1.5
Yijye Chern cohort 1 (2020)	OS	HSP47	PCR	Primary tissue	NA	Mixed	No chemotherapy	>200	<1.5
Yijye Chern cohort 2 (2020)	OS	HSP47	PCR	Primary tissue	NA	Mixed	No chemotherapy	>200	<1.5
Koichiro Mori (2020)	OS	HSP47	PCR	Primary tissue	Postoperative	Mixed	No chemotherapy		<1.5
Michal Vocka (2019)	OS	HSP60	ELISA	Serum	Prior to mCRC treatment or palliative therapy	metastatic	NA	≤200	≥1.5
Myunghee Kang (2023)	OS	HSP60	IHC	Primary tissue	Postoperative	Mixed	No chemotherapy	>200	<1.5
Judit Kocsis and Balázs Madaras (2010)	OS	HSP70	ELISA	Serum	Post-diagnosis	Mixed	With chemotherapy	≤200	<1.5
Judit Kocsis (2011)	OS	HSP70	ELISA	Serum	Post-diagnosis	Mixed	With chemotherapy	≤200	<1.5
Hiroyuki Takahashi cohort 1 (2011)	OS	GRP75/78	IHC	Primary tissue	Postoperative	Mixed	With chemotherapy	>200	<1.5
Hiroyuki Takahashi cohort 2 (2011)	OS	GRP94	IHC	Primary tissue	Postoperative	Mixed	With chemotherapy	>200	<1.5
Perri Rozenberg cohort 1 (2013)	OS	HSP70	ELISA	Serum	Postoperative	NA	With chemotherapy	≤200	NA
Perri Rozenberg cohort 2 (2013)	OS	GRP75/78	ELISA	Serum	Postoperative	NA	With chemotherapy	≤200	NA
Ritta Jubran cohort 1 (2017)	OS	HSP70	ELISA	Serum	Post-diagnosis	Mixed	With chemotherapy	>200	<1.5
Ritta Jubran cohort 2 (2017)	OS	GRP75/78	ELISA	Serum	Post-diagnosis	Mixed	With chemotherapy	>200	<1.5
Xin Wang (2019)	OS	HSP70	IHC	Primary tissue	Post-diagnosis	Mixed	With chemotherapy	≤200	≥1.5
Shuming Zhang (2019)	OS	HSP90	IHC	Primary tissue	Postoperative	Mixed	No chemotherapy	≤200	<1.5
Jae Seok Lee (2020)	OS	GRP94	IHC	Primary tissue	Postoperative	NA	No chemotherapy	>200	<1.5
Dávid Fodor (2023)	OS	HSP90	IHC	Primary tissue	Post-diagnosis	Nonmetastatic	With chemotherapy	≤200	<1.5
Zhenzhen CAO (2025)	OS	HSP90	ELISA	Serum	Post-diagnosis	Nonmetastatic	No chemotherapy	≤200	<1.5
Nan JIANG (2025)	OS	HSP90	ELISA	Serum	Post-diagnosis	Nonmetastatic	No chemotherapy	≤200	≥1.5
Maria Anna Kalioraki (2019)	RFS	HSP27	PCR	Primary tissue	Postoperative	Mixed	No chemotherapy	≤200	<1.5
Tong Tong Zhang (2015)	DFS	HSP40	IHC	Primary tissue	Postoperative	Mixed	No chemotherapy	≤200	≥1.5
Myunghee Kang cohort 1 (2023)	DSS	HSP60	IHC	Primary tissue	Postoperative	Mixed	No chemotherapy	>200	<1.5
Myunghee Kang cohort 1 (2023)	RFS	HSP60	IHC	Primary tissue	NA	Mixed	No chemotherapy	>200	<1.5
Min Gyoung Pak (2017)	DSS	HSP90	IHC	Primary tissue	Postoperative	Mixed	No chemotherapy	>200	<1.5
Coralie Dorard (2011)	DFS	HSP110 ΔE9/HS P110 wt	PCR	Primary tissue	NA	Nonmetastatic	With chemotherapy	≤200	NA
Jung Ho Kim cohort 1 (2014)	DFS	HSP110 wt	IHC	Primary tissue	Post-diagnosis	Nonmetastatic	With chemotherapy	≤200	<1.5
Jung Ho Kim cohort 2 (2014)	DFS	HSP110 T17 deletion	PCR	Primary tissue	Post-diagnosis	Nonmetastatic	With chemotherapy	≤200	<1.5
Ada Collura (2014)	RFS	HSP110 T17 deletion	PCR	Primary tissue	Postoperative	Nonmetastatic	With chemotherapy	>200	<1.5
Jung Ho Kim (2015)	DFS	HSP110 wt	IHC	Primary tissue	Post-diagnosis	Nonmetastatic	With chemotherapy	≤200	NA
Hyeon Jeong Oh cohort 1 (2017)	DFS	HSP110 wt	IHC	Primary tissue	Post-diagnosis	Mixed	NA	≤200	<1.5
Hyeon Jeong Oh cohort 2 (2017)	DFS	HSP110 T17 deletion	PCR	Primary tissue	Post-diagnosis	Mixed	NA	≤200	<1.5
Gaelle Tachon cohort 1 (2022)	TTR	HSP110 wt	IHC	Primary tissue	Post-diagnosis	Mixed	With chemotherapy	>200	<1.5
Gaelle Tachon cohort 2 (2022)	TTR	HSP110 T17 deletion	PCR	Primary tissue	Post-diagnosis	Mixed	With chemotherapy	>200	<1.5